Neurogene Inc. (NASDAQ:NGNE) Receives Average Rating of “Moderate Buy” from Analysts

Neurogene Inc. (NASDAQ:NGNE) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $44.00.

NGNE has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Neurogene in a report on Tuesday, January 13th. Wall Street Zen downgraded Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Finally, Lifesci Capital assumed coverage on Neurogene in a report on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price for the company.

Institutional Investors Weigh In On Neurogene

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Balyasny Asset Management L.P. acquired a new position in Neurogene in the 3rd quarter valued at about $12,114,000. Jennison Associates LLC raised its position in shares of Neurogene by 35.3% during the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after buying an additional 138,999 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Neurogene by 122.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 162,018 shares of the company’s stock valued at $3,338,000 after buying an additional 89,216 shares during the period. Bank of America Corp DE grew its position in Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock worth $1,426,000 after acquiring an additional 42,880 shares during the period. Finally, Schroder Investment Management Group purchased a new position in Neurogene in the second quarter worth approximately $451,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Stock Up 0.7%

Neurogene stock opened at $17.00 on Friday. The company has a fifty day simple moving average of $18.97 and a 200-day simple moving average of $21.62. The firm has a market capitalization of $263.33 million, a price-to-earnings ratio of -4.14 and a beta of 1.59. Neurogene has a 52-week low of $6.88 and a 52-week high of $37.27.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.27. On average, research analysts anticipate that Neurogene will post -4.27 EPS for the current fiscal year.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.